DK2403878T3 - Cadm1-specifikke fuldt humane antistoffer - Google Patents
Cadm1-specifikke fuldt humane antistoffer Download PDFInfo
- Publication number
- DK2403878T3 DK2403878T3 DK10708470.9T DK10708470T DK2403878T3 DK 2403878 T3 DK2403878 T3 DK 2403878T3 DK 10708470 T DK10708470 T DK 10708470T DK 2403878 T3 DK2403878 T3 DK 2403878T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibody
- cadm1
- seq
- human
- antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (15)
1. Isoleret monoklonalt antistof, eller antigenbindende del deraf, eller antistoffragment, der binder en epitop på humant CADM1 og omfatter en variabel tungkæderegion, der omfatter aminosyresekvensen ifølge SEQ ID NO: 19, 20, eller 21 og en variabel letkæderegion, der omfatter aminosyresekvensen ifølge SEQ ID NO: 22, 23 eller 24.
2. Isoleret monoklonalt antistof, eller antigenbindende del deraf, eller antistoffragment, der binder en epitop på humant CADM1 og som omfatter: (a) en variabel tungkæderegion CDR1, der omfatter SEQ ID NO: 1, en variabel tungkæderegion CDR2, der omfatter SEQ ID NO: 4, en variabel tungkæderegion CDR3, der omfatter SEQ ID NO: 7, en variabel letkæderegion CDR1, der omfatter SEQ ID NO: 10, en variabel letkæderegion CDR2, der omfatter SEQ ID NO: 13 og en variabel letkæderegion CDR3, der omfatter SEQ ID NO: 16; eller (b) en variabel tungkæderegion CDR1, der omfatter SEQ ID NO: 2, en variabel tungkæderegion CDR2, der omfatter SEQ ID NO: 5, en variabel tungkæderegion CDR3, der omfatter SEQ ID NO: 8, en variabel letkæderegion CDR1, der omfatter SEQ ID NO: 11, en variabel letkæderegion CDR2, der omfatter SEQ ID NO: 14 og en variabel letkæderegion CDR3, der omfatter SEQ ID NO: 17; eller (c) en variabel tungkæderegion CDR1, der omfatter SEQ ID NO: 3, en variabel tungkæderegion CDR2, der omfatter SEQ ID NO: 6, en variabel tungkæderegion CDR3, der omfatter SEQ ID NO: 9, en variabel letkæderegion CDR1, der omfatter SEQ ID NO: 12, en variabel letkæderegion CDR2, der omfatter SEQ ID NO: 15 og en variabel letkæderegion CDR3, der omfatter SEQ ID NO: 18.
3. Antistof ifølge krav 1 eller krav 2: (A) hvor antistoffet er er et fuldlængde antistof af en IgGl-, IgG2-, IgG3- eller IgG4-isotypc; (B) hvor antistoffet er udvalgt fra gruppen bestående af: et fuldt antistof, et antistoffragment, et humaniseret antistof, et humant antistof, et enkeltkædeantistof, et manipuleret antistof, der resulterer i øget binding til Fc-receptorer og/eller øget potens for ADCC, og et bispecifikt antistof; (C) hvor antistoffet, der er konjugeret til et terapeutisk middel, fortrinsvis hvor det terapeutiske middel er et cytotoksin eller en radioaktiv isotop; eller (D) hvor antistoffet binder til humant CADM1 med en EC50 i intervallet fra < 50 nM, fortrinsvis hvor antistoffet binder til humant CADM1 med en EC50 i intervallet fra < 10 nM, og mere fortrinsvis hvor antistoffet binder til humant CADM1 med en EC50 i intervallet fra < 1 nM.
4. Sammensætning, der omfatter det isolerede antistof, den antigenbindende del eller antistoffragmentet, der binder en epitop på humant CADM1 ifølge krav 1 eller krav 2, og en farmaceutisk acceptabel bærer.
5. Isoleret nukleinsyremolekyle, der koder for tung- eller letkæden af antistoffet eller den antigenbindende del eller antistoffragmentet, der binder en epitop på humant CADM1 ifølge krav 1 eller krav 2; eller en ekspressionsvektor, der omfatter nukleinsyremolekylet; eller en værtscelle, der omfatter ekspressionsvektoren.
6. Fremgangsmåde til fremstilling af et anti-CADMl-antistof, hvilken fremgangsmåde omfatter følgende trin: opnåelse af en værtscelle, der indeholder ét eller flere nukleinsyremolekyler, der koder for antistoffet ifølge krav 1 eller krav 2; dyrkning af værtscellen i en værtscellekultur; tilvejebringelse af værtsccllcdyrkningsbctingclscr, hvor det ene eller flere nukleinsyremolekyler udtrykkes; og genvinding af antistoffet fra værtscellen eller fra værtscellekulturen.
7. Isoleret monoklonalt antistof, eller antigenbindende del deraf, eller antistoffragment som defineret i krav 1 eller krav 2 til anvendelse i en fremgangsmåde til behandling eller forebyggelse af en sygdom forbundet med målceller, der udtrykker CADM1, fortrinsvis hvor sygdommen er en human cancer, og mere fortrinsvis hvor den humane cancer er udvalgt fra gruppen bestående af: småcellet lungecancer, T-celleleukæmi hos voksne, ikke-småcellet lungecancer (herunder pladeepitelkarcinomer og adenokarcinomer), melanom, brystcancer, colorektalcancer, ovariecancer, prostatacancer, neuroendokrine cancere, herunder cancere i lunge, binyre, hypofyse, mave-tarm-kanal, nyre, lever (herunder hepatocellulære karcinomer), pankreas (herunder insulinomer og glueagonomer), glioblastomer og carcinoide tumorer, herunder tumorer i pankreas, lunge, mave-tarm-kanal, lever og nyre.
8. Isoleret monoklonalt antistof eller antigenbindende del deraf, eller antistoffragment ifølge krav 1 eller krav 2, der binder en epitop på humant CADM1 og omfatter en variabel tungkæderegion og en variabel letkæderegion udvalgt fra gruppen bestående af: den variable tungkæderegions aminosyresekvens ifølge SEQ ID NO: 19 og den variable letkæderegions aminosyresekvens ifølge SEQ ID NO: 22; den variable tungkæderegions aminosyresekvens ifølge SEQ ID NO: 20 og den variable letkæderegions aminosyresekvens ifølge SEQ ID NO: 23; og den variable tungkæderegions aminosyresekvens ifølge SEQ ID NO: 21 og den variable letkæderegions aminosyresekvens ifølge SEQ ID NO: 24.
9. Isoleret antistof ifølge krav 8: hvor antistoffet er udvalgt fra gruppen bestående af: et fuldt antistof, antistoffragment, et humaniseret antistof, et humant antistof, et enkeltkædeantistof, et manipuleret antistof, der resulterer i øget binding til Fe-receptorer og/eller øget potens for ADCC, og et bispecifikt antistof.
10. Sammensætning, der omfatter det isolerede antistof eller den antigenbindende del deraf ifølge krav 8 og en farmaceutisk acceptabel bærer.
11. Isoleret nukleinsyremolekyle, der koder for tung- eller letkæden af det isolerede antistof eller den antigenbindende del deraf ifølge krav 8; eller en ekspressionsvektor, der omfatter nukleinsyremolekylet; eller en værtscelle, der omfatter ekspressionsvektoren.
12. Hybridom, der udtrykker antistoffet eller den antigenbindende del eller antistoffragmentet, der binder en epitop på humant CADM1 ifølge et hvilket som helst af kravene 1,2 eller 8.
13. Fremgangsmåde til fremstilling af antistoffet ifølge et hvilket som helst af kravene 1, 2 eller 8, der omfatter følgende trin: immunisering af et transgent dyr, der omfatter human immunoglobulingener med et CADM1-peptid; genvinding af B-celler fra det transgene dyr; frembringelse af hybridomer fra B-celleme; udvælgelse af hybridomer, der udtrykker antistoffer, der binder CADM1; og genvinding af antistofferne, der binder CADM1 ffa de udvalgte hybridomer.
14. Fremgangsmåde til fremstilling af anti-CADMl-antistoffer omfattende følgende trin: immunisering af et transgent dyr, der omfatter humane immunoglobulingener med et CADM1-peptid; genvinding af mRNA fra B-cellerne af det transgene dyr; omdannelse af mRNA’et til cDNA; ekspression af cDNA’et i phager, således at anti-CADMl-antistoffer, der er kodet for af cDNA’et, præsenteres på overfladen af phageme; udvælgelse af phager, der præsenterer anti-CADMl-antistoffer; genvinding af nukleinsyremolekyler fra de udvalgte phager, der koder for anti-CADMl-immunoglobulineme; ekspression af de genvundne nukleinsyremolekyler i en værtscelle; og genvinding af antistoffer som defineret i et hvilket som helst af kravene 1, 2 eller 8 ffa værtscellen, der binder CADM1.
15. Immunkonjugat, der omfatter (i) et isoleret antistof ifølge krav 8 eller krav 9 og (ii) et terapeutisk middel.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20939009P | 2009-03-05 | 2009-03-05 | |
US20947109P | 2009-03-05 | 2009-03-05 | |
PCT/US2010/026315 WO2010102175A1 (en) | 2009-03-05 | 2010-03-05 | Fully human antibodies specific to cadm1 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2403878T3 true DK2403878T3 (da) | 2017-09-18 |
Family
ID=42144944
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10708470.9T DK2403878T3 (da) | 2009-03-05 | 2010-03-05 | Cadm1-specifikke fuldt humane antistoffer |
Country Status (25)
Country | Link |
---|---|
US (2) | US8420084B2 (da) |
EP (1) | EP2403878B1 (da) |
JP (1) | JP5816558B2 (da) |
KR (1) | KR101769160B1 (da) |
CN (1) | CN102341412B (da) |
AU (1) | AU2010221186B2 (da) |
BR (1) | BRPI1009232B1 (da) |
CA (1) | CA2753702C (da) |
CY (1) | CY1119539T1 (da) |
DK (1) | DK2403878T3 (da) |
EA (1) | EA028336B1 (da) |
ES (1) | ES2639026T3 (da) |
HR (1) | HRP20171274T1 (da) |
HU (1) | HUE034196T2 (da) |
IL (1) | IL214779A (da) |
LT (1) | LT2403878T (da) |
ME (1) | ME02842B (da) |
MX (1) | MX2011009220A (da) |
NZ (1) | NZ594682A (da) |
PL (1) | PL2403878T3 (da) |
PT (1) | PT2403878T (da) |
SG (1) | SG173742A1 (da) |
UA (1) | UA102891C2 (da) |
WO (1) | WO2010102175A1 (da) |
ZA (1) | ZA201105918B (da) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7989160B2 (en) | 2006-02-13 | 2011-08-02 | Alethia Biotherapeutics Inc. | Polynucleotides and polypeptide sequences involved in the process of bone remodeling |
US8168181B2 (en) | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
DK2069793T3 (da) | 2006-08-29 | 2017-04-24 | Oxford Biotherapeutics Ltd | Identifikation af protein i forbindelse med hepatocellulært karcinom, glioblastom og lungecancer |
PL2403878T3 (pl) * | 2009-03-05 | 2017-12-29 | E. R. Squibb & Sons, L.L.C. | W pełni ludzkie przeciwciała specyficzne dla CADM1 |
WO2012119989A2 (en) | 2011-03-04 | 2012-09-13 | Oryzon Genomics, S.A. | Methods and antibodies for the diagnosis and treatment of cancer |
CN104507969A (zh) | 2012-07-19 | 2015-04-08 | 阿莱斯亚生物疗法股份有限公司 | 抗siglec-15抗体 |
JP6440968B2 (ja) * | 2013-05-28 | 2018-12-19 | 国立大学法人 宮崎大学 | IgSF4/TSLC1/CADM1を特異的に認識できる抗体 |
EP3383904A4 (en) * | 2015-11-19 | 2019-12-04 | Zeling Cai | CTLA-4 ANTIBODIES AND USES THEREOF |
JP7229503B2 (ja) * | 2018-03-16 | 2023-02-28 | 国立大学法人 東京大学 | CADM1v9認識抗体 |
AU2018447127A1 (en) * | 2018-10-22 | 2021-05-27 | Shanghai GenBase Biotechnology Co., Ltd. | Anti-CLDN128.2 antibody and uses thereof |
JPWO2022239766A1 (da) * | 2021-05-11 | 2022-11-17 | ||
TW202321296A (zh) * | 2021-10-06 | 2023-06-01 | 美商鏈接免疫療法公司 | 抗間皮素抗原結合分子及其用途 |
KR20230062691A (ko) | 2021-10-29 | 2023-05-09 | 주식회사 이뮤노로지컬디자이닝랩 | Cadm1에 특이적으로 결합하는 키메릭 항원 수용체 및 이의 용도 |
KR20230061710A (ko) | 2021-10-29 | 2023-05-09 | 주식회사 이뮤노로지컬디자이닝랩 | Cadm1을 인식하는 재조합 단백질 및 이를 유효성분으로 포함하는 암의 치료용 약학적 조성물 |
WO2023163094A1 (ja) * | 2022-02-25 | 2023-08-31 | 日本電気株式会社 | 成人t細胞白血病の治療又は予防のための医薬組成物 |
JP7270944B1 (ja) * | 2022-09-13 | 2023-05-11 | 学校法人近畿大学 | 抗cadm1抗体またはその抗原結合断片 |
Family Cites Families (188)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4631190A (en) | 1981-06-26 | 1986-12-23 | Shen Wei C | Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers |
US5144011A (en) | 1981-06-26 | 1992-09-01 | Boston University | Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
US4698420A (en) | 1985-02-25 | 1987-10-06 | Xoma Corporation | Antibody hybrid molecules and process for their preparation |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4954617A (en) | 1986-07-07 | 1990-09-04 | Trustees Of Dartmouth College | Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
EP0318554B2 (en) | 1987-05-21 | 2005-01-12 | Micromet AG | Targeted multifunctional proteins |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
AU634186B2 (en) | 1988-11-11 | 1993-02-18 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
WO1990006952A1 (en) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
DK0463151T3 (da) | 1990-01-12 | 1996-07-01 | Cell Genesys Inc | Frembringelse af xenogene antistoffer |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5864026A (en) | 1990-06-11 | 1999-01-26 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue selex |
US5712375A (en) | 1990-06-11 | 1998-01-27 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue selex |
US5763566A (en) | 1990-06-11 | 1998-06-09 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue SELEX |
US6261774B1 (en) | 1990-06-11 | 2001-07-17 | Gilead Sciences, Inc. | Truncation selex method |
US5789157A (en) | 1990-06-11 | 1998-08-04 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue selex |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
DE69133476T2 (de) | 1990-08-29 | 2006-01-05 | GenPharm International, Inc., Palo Alto | Transgene Mäuse fähig zur Produktion heterologer Antikörper |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
AU665221B2 (en) | 1991-12-02 | 1995-12-21 | Cambridge Antibody Technology Limited | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
AU4116793A (en) | 1992-04-24 | 1993-11-29 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
GB9223377D0 (en) | 1992-11-04 | 1992-12-23 | Medarex Inc | Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes |
AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6838254B1 (en) | 1993-04-29 | 2005-01-04 | Conopco, Inc. | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
AU732961B2 (en) | 1995-05-03 | 2001-05-03 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue selex |
US6013443A (en) | 1995-05-03 | 2000-01-11 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue SELEX |
WO1997012862A1 (en) | 1995-10-03 | 1997-04-10 | The Scripps Research Institute | Cbi analogs of cc-1065 and the duocarmycins |
US6642360B2 (en) | 1997-12-03 | 2003-11-04 | Genentech, Inc. | Secreted polypeptides that stimulate release of proteoglycans from cartilage |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US7368531B2 (en) | 1997-03-07 | 2008-05-06 | Human Genome Sciences, Inc. | Human secreted proteins |
US7411051B2 (en) | 1997-03-07 | 2008-08-12 | Human Genome Sciences, Inc. | Antibodies to HDPPA04 polypeptide |
GB2339430A (en) | 1997-05-21 | 2000-01-26 | Biovation Ltd | Method for the production of non-immunogenic proteins |
JP2002503228A (ja) | 1997-05-22 | 2002-01-29 | ザ スクリップス リサーチ インスティテュート | デュオカルマイシンおよびcc−1065の類似体 |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
JP2002505850A (ja) | 1997-12-03 | 2002-02-26 | ジェネンテック・インコーポレーテッド | ポリペプチド及び同じものをコードしている核酸 |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
DE69942021D1 (de) | 1998-04-20 | 2010-04-01 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
CA2327457A1 (en) | 1998-05-07 | 1999-11-11 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
ATE415480T1 (de) | 1998-08-07 | 2008-12-15 | Immunex Corp | B7l-1 moleküle |
EP1102848B1 (en) | 1998-08-07 | 2010-10-13 | Immunex Corporation | Molecules designated ldcam |
US20030055231A1 (en) | 1998-10-28 | 2003-03-20 | Jian Ni | 12 human secreted proteins |
JP2002530062A (ja) | 1998-10-28 | 2002-09-17 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 12個のヒト分泌タンパク質 |
WO2000028032A2 (en) | 1998-11-12 | 2000-05-18 | Incyte Pharmaceuticals, Inc. | Human cell surface receptor proteins |
CA2347677A1 (en) | 1998-12-01 | 2000-06-08 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
PL220113B1 (pl) | 1999-01-15 | 2015-08-31 | Genentech Inc | Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc |
EP1616878B1 (en) | 1999-03-23 | 2008-12-10 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
EP2270150B2 (en) | 1999-04-09 | 2019-08-07 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
US7129338B1 (en) | 1999-07-08 | 2006-10-31 | Research Association For Biotechnology | Secretory protein or membrane protein |
US6387620B1 (en) | 1999-07-28 | 2002-05-14 | Gilead Sciences, Inc. | Transcription-free selex |
JP2003516718A (ja) | 1999-07-29 | 2003-05-20 | メダレックス インク | HER2/neuに対するヒトモノクローナル抗体 |
EP1792991A1 (en) | 1999-08-24 | 2007-06-06 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
AU6802801A (en) | 2000-03-01 | 2001-09-24 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
WO2002014577A1 (fr) * | 2000-08-04 | 2002-02-21 | Japan Lifeline Co., Ltd | Procede pour produire un element metallique cylindrique a paroi mince |
DE60136212D1 (de) | 2000-08-15 | 2008-11-27 | Univ Johns Hopkins Med | Diagnose und behandlung von tumor-suppressor assoziierten krankheiten |
AU2001292561A1 (en) | 2000-09-01 | 2002-03-13 | Hyseq, Inc. | Nucleic acids and polypeptides |
CA2421447C (en) | 2000-09-08 | 2012-05-08 | Universitat Zurich | Collections of repeat proteins comprising repeat modules |
WO2002047466A2 (en) * | 2000-10-27 | 2002-06-20 | The Johns Hopkins University School Of Medicine | Beta-secretase transgenic organisms, anti-beta-secretase antibodies, and methods of use thereof |
WO2002066643A2 (en) | 2000-11-13 | 2002-08-29 | Curagen Corporation | Proteins, polynucleotides encoding them and methods of using the same |
US7041870B2 (en) | 2000-11-30 | 2006-05-09 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
US20050048512A1 (en) | 2001-04-26 | 2005-03-03 | Avidia Research Institute | Combinatorial libraries of monomer domains |
US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
US20040175756A1 (en) | 2001-04-26 | 2004-09-09 | Avidia Research Institute | Methods for using combinatorial libraries of monomer domains |
PT1390535E (pt) | 2001-04-26 | 2010-10-04 | Amgen Mountain View Inc | Bibliotecas combinatórias de domínios monoméricos |
US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
US20060223114A1 (en) | 2001-04-26 | 2006-10-05 | Avidia Research Institute | Protein scaffolds and uses thereof |
US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
JP4115281B2 (ja) | 2001-05-11 | 2008-07-09 | キリンファーマ株式会社 | ヒト抗体λ軽鎖遺伝子を含むヒト人工染色体、および子孫伝達可能な該ヒト人工染色体を含む非ヒト動物 |
EP1421203A4 (en) | 2001-05-17 | 2005-06-01 | Diversa Corp | NEW ANTIGEN-BINDING MOLECULES FOR THERAPEUTIC, DIAGNOSTIC, PROPHYLACTIC, ENZYMATIC, INDUSTRIAL AND AGRICULTURAL APPLICATIONS AND METHOD FOR THE PRODUCTION AND SCREENING THEREOF |
KR20030033007A (ko) | 2001-05-31 | 2003-04-26 | 코울터 파머수티컬, 인코포레이티드 | 세포독소, 약물전구체, 링커 및 이에 유용한 안정화제 |
DE60239679D1 (de) | 2001-06-11 | 2011-05-19 | Medarex Inc | Methode für die ausarbeitung von cd10-aktivierten prodrug-verbindungen |
AU2002319402B2 (en) | 2001-06-28 | 2008-09-11 | Domantis Limited | Dual-specific ligand and its use |
CA2459308A1 (en) | 2001-09-07 | 2003-03-20 | Dale L. Boger | Cbi analogues of cc-1065 and the duocarmycins |
US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
WO2003035835A2 (en) | 2001-10-25 | 2003-05-01 | Genentech, Inc. | Glycoprotein compositions |
AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
EA200401325A1 (ru) | 2002-04-09 | 2005-04-28 | Киова Хакко Когио Ко., Лтд. | Клетки с модифицированным геномом |
EP2366718A3 (en) | 2002-06-28 | 2012-05-02 | Domantis Limited | Ligand |
EP1558647B1 (en) | 2002-11-08 | 2015-06-10 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
JP2006523090A (ja) | 2002-12-27 | 2006-10-12 | ドマンティス リミテッド | リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体 |
US20060228710A1 (en) | 2003-02-14 | 2006-10-12 | Morris David W | Novel therapeutic targets in cancer |
EP1464709B1 (en) | 2003-03-31 | 2007-12-26 | Stichting Researchfonds Pathologie | Detection of HPV-induced invasive cancers and their precursor lesions with invasive potential |
DE10316701A1 (de) | 2003-04-09 | 2004-11-04 | Hinzmann, Bernd, Dr. | Humane Nukleinsäuresequenzen aus Bronchialkarzinomen |
DE602004025799D1 (de) | 2003-04-15 | 2010-04-15 | Glaxosmithkline Llc | Humane il-18 substitutionsmutanten und deren konjugate |
AU2004239065B2 (en) | 2003-05-14 | 2008-05-15 | Domantis Limited | A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire |
CN1845938B (zh) | 2003-06-30 | 2010-05-26 | 杜门蒂斯有限公司 | 多肽 |
MXPA06000974A (es) | 2003-07-25 | 2006-08-31 | Amgen Inc | Antagonistas y agonistas de ldcam y metodos para su uso. |
US7807392B1 (en) | 2003-09-15 | 2010-10-05 | Celera Corporation | Lung disease targets and uses thereof |
CA2543360A1 (en) | 2003-10-24 | 2005-05-06 | Joost A. Kolkman | Ldl receptor class a and egf domain monomers and multimers |
JP4227881B2 (ja) | 2003-11-13 | 2009-02-18 | 財団法人宮崎県産業支援財団 | 成人t細胞白血病診断薬 |
AU2005216251B2 (en) | 2004-02-23 | 2011-03-10 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
CA2564076C (en) | 2004-05-19 | 2014-02-18 | Medarex, Inc. | Chemical linkers and conjugates thereof |
US7691962B2 (en) | 2004-05-19 | 2010-04-06 | Medarex, Inc. | Chemical linkers and conjugates thereof |
US7541330B2 (en) | 2004-06-15 | 2009-06-02 | Kosan Biosciences Incorporated | Conjugates with reduced adverse systemic effects |
US20060008844A1 (en) | 2004-06-17 | 2006-01-12 | Avidia Research Institute | c-Met kinase binding proteins |
BRPI0516284A (pt) | 2004-09-23 | 2008-09-02 | Genentech Inc | anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto |
ZA200704338B (en) | 2004-10-29 | 2009-03-25 | Genentech Inc | Novel gene disruptions, compositions and methods relating thereto |
CA2587424A1 (en) | 2004-11-16 | 2006-05-26 | Avidia Research Institute | Protein scaffolds and uses thereof |
JP2008528010A (ja) | 2005-01-31 | 2008-07-31 | アブリンクス ナームローゼ フェンノートシャップ | 重鎖抗体の可変ドメイン配列を作出する方法 |
JP4942644B2 (ja) * | 2005-02-28 | 2012-05-30 | 株式会社抗体研究所 | 抗IgSF4抗体及びその利用 |
US7608413B1 (en) | 2005-03-25 | 2009-10-27 | Celera Corporation | Kidney disease targets and uses thereof |
US7714016B2 (en) | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
JP4536588B2 (ja) | 2005-05-11 | 2010-09-01 | 財団法人宮崎県産業支援財団 | 成人t細胞白血病の診断器具 |
US7842467B1 (en) | 2005-05-12 | 2010-11-30 | Celera Corporation | Breast disease targets and uses thereof |
JP5131946B2 (ja) | 2005-09-13 | 2013-01-30 | 国立大学法人 東京大学 | がんの診断、処置および/または予防、および/または浸潤・転移の抑制のための方法、システムおよび組成物ならびに関連するスクリーニング方法 |
JP5290756B2 (ja) | 2005-09-26 | 2013-09-18 | メダレックス インコーポレイテッド | 抗体−薬剤コンジュゲート及びその使用 |
AU2006294644A1 (en) | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Proteinaceous pharmaceuticals and uses thereof |
US7847105B2 (en) | 2005-10-26 | 2010-12-07 | Medarex, Inc. | Methods and compounds for preparing CC-1065 analogs |
WO2007059404A2 (en) | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
SG10201600950TA (en) | 2005-11-28 | 2016-03-30 | Genmab As | Recombinant monovalent antibodies and methods for production thereof |
JP5131751B2 (ja) | 2005-12-28 | 2013-01-30 | 国立大学法人 東京大学 | 小細胞肺がんの診断のための方法、システムおよび組成物ならびに関連するスクリーニング方法 |
US7842291B1 (en) | 2006-05-22 | 2010-11-30 | Celera Corporation | Methods and compositions for diagnosing and treating diseases |
EP2975057A1 (en) | 2006-07-10 | 2016-01-20 | Fujita Health University | Novel anti-cd73 antibody |
EP2057465A4 (en) | 2006-08-09 | 2010-04-21 | Homestead Clinical Corp | SPECIFIC ORGAN PROTEINS AND METHODS OF USE |
DK2069793T3 (da) * | 2006-08-29 | 2017-04-24 | Oxford Biotherapeutics Ltd | Identifikation af protein i forbindelse med hepatocellulært karcinom, glioblastom og lungecancer |
AU2007325931A1 (en) | 2006-11-02 | 2008-06-05 | Yale University | Assessment of oocyte competence |
EP1918299A1 (en) | 2006-11-03 | 2008-05-07 | Universite De Geneve | Modulators of cell adhesion molecules and use thereof |
TWI412367B (zh) | 2006-12-28 | 2013-10-21 | Medarex Llc | 化學鏈接劑與可裂解基質以及其之綴合物 |
CA2682916A1 (en) | 2007-04-06 | 2008-11-27 | Source Precision Medicine, Inc. D/B/A Source Mdx | Gene expression profiling for identification, monitoring, and treatment of cervical cancer |
WO2008142693A2 (en) | 2007-05-22 | 2008-11-27 | Yeda Research And Development Co. Ltd. | Regulation of myelination by nectin-like (necl) molecules |
ES2550754T3 (es) * | 2007-08-07 | 2015-11-12 | Oxford Biotherapeutics Ltd. | Proteína matriptasa y usos de la misma |
EP2190468A2 (en) | 2007-08-30 | 2010-06-02 | Genentech, Inc. | Methods and compositions for modulating t cells |
EP2195658A2 (en) | 2007-09-28 | 2010-06-16 | Royal College of Surgeons in Ireland | A method of assessing colorectal cancer status in an individual |
EP2128259A1 (en) | 2008-05-27 | 2009-12-02 | Koninklijke Philips Electronics N.V. | Therapy delivery and monitoring using a gene of interest-reporter fusion protein and optical imaging |
JP2012516445A (ja) | 2009-01-27 | 2012-07-19 | ホロジック,インコーポレイテッド | 体液における新生児敗血症の検出のためのバイオマーカー |
PL2403878T3 (pl) | 2009-03-05 | 2017-12-29 | E. R. Squibb & Sons, L.L.C. | W pełni ludzkie przeciwciała specyficzne dla CADM1 |
-
2010
- 2010-03-05 PL PL10708470T patent/PL2403878T3/pl unknown
- 2010-03-05 HU HUE10708470A patent/HUE034196T2/en unknown
- 2010-03-05 EA EA201101242A patent/EA028336B1/ru unknown
- 2010-03-05 ME MEP-2017-194A patent/ME02842B/me unknown
- 2010-03-05 CA CA2753702A patent/CA2753702C/en active Active
- 2010-03-05 WO PCT/US2010/026315 patent/WO2010102175A1/en active Application Filing
- 2010-03-05 EP EP10708470.9A patent/EP2403878B1/en active Active
- 2010-03-05 CN CN201080010338.5A patent/CN102341412B/zh active Active
- 2010-03-05 KR KR1020117023235A patent/KR101769160B1/ko active IP Right Grant
- 2010-03-05 ES ES10708470T patent/ES2639026T3/es active Active
- 2010-03-05 MX MX2011009220A patent/MX2011009220A/es active IP Right Grant
- 2010-03-05 SG SG2011059292A patent/SG173742A1/en unknown
- 2010-03-05 US US13/254,752 patent/US8420084B2/en active Active
- 2010-03-05 NZ NZ594682A patent/NZ594682A/xx unknown
- 2010-03-05 DK DK10708470.9T patent/DK2403878T3/da active
- 2010-03-05 UA UAA201111731A patent/UA102891C2/uk unknown
- 2010-03-05 PT PT107084709T patent/PT2403878T/pt unknown
- 2010-03-05 JP JP2011553127A patent/JP5816558B2/ja active Active
- 2010-03-05 LT LTEP10708470.9T patent/LT2403878T/lt unknown
- 2010-03-05 BR BRPI1009232-3A patent/BRPI1009232B1/pt active IP Right Grant
- 2010-03-05 AU AU2010221186A patent/AU2010221186B2/en active Active
-
2011
- 2011-08-12 ZA ZA2011/05918A patent/ZA201105918B/en unknown
- 2011-08-22 IL IL214779A patent/IL214779A/en active IP Right Grant
-
2012
- 2012-12-27 US US13/728,059 patent/US20130156788A1/en not_active Abandoned
-
2017
- 2017-08-22 HR HRP20171274TT patent/HRP20171274T1/hr unknown
- 2017-08-29 CY CY20171100907T patent/CY1119539T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2403878T3 (da) | Cadm1-specifikke fuldt humane antistoffer | |
AU2008308956B2 (en) | Human antibodies that bind mesothelin, and uses thereof | |
US9217033B2 (en) | Monoclonal antibodies against Glypican-3 | |
MX2008006792A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use |